Hottod Thank you for replying to my post and yes I was aware of the so-called seasonal factors that may negatively impact on the Q1 2025 Daybue revenue.Here are just a few more items as to why I suggest the upcoming Daybue revenue may be better than expected: *Q 4 2024 patient discontinuations improved by about 15% over Q3 2024.Initial dose titration apparentlly improves tolerability suggesting that the future persistence rate for new patients can be higher than the early experience.[refer 2024 Annual Report]
*60% of patients have been in therapy for more than one year resulting in sales being more predictable.[refer 2024 Annual Report]
*A director buying shares on market is always a positive signal that the future is looking healthy.
*Q4 2024 revenue compared to Q2 2024 revenue indicates a revenue increase of $12.1M[14.3% above Q2] with $88M being the midpoint between the two revenue periods.The suggested $88M revenue for Q1 2025 reflects a decrease from the previous quarter of $8.7M[9.0%] and reflects the equivalent of 71.9% of the previously mentioned revenue increases. *Neuren management has already indicated that Q1 2025 Daybue revenue will be less than Q4 2024 but has not indicated by how much.[refer 2024 Annual Report]
*Having said all of the above Acadia last trading closed @$14.83per share with shorts running at 12.6% of the float just to prove why everything above is wrong. Kens
NEU Price at posting:
$11.34 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)